NSE: GLAND · 11 November 2026
- Gland Pharma Ltd. (GLAND) moved up 0.30% today, closing at ₹3,312.40 compared to its previous close of ₹3,302.40. The stock traded within a daily range of ₹3,281.70 to ₹3,770.00, touching a fresh 52-week high of ₹3,374.00 during the session.
- Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 9, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across biopharma and healthcare services, holding degrees from Johns Hopkins University and MIT. He will lead M&A and strategic investments across the US, China, Singapore, and other international markets.
- Trading volume was 0.27 times the 20-day average daily volume.
Why is Gland Pharma share price rising on 11 November 2026?
Gland Pharma Ltd. (GLAND) moved up 0.30% today, closing at ₹3,312.40 compared to its previous close of ₹3,302.40. The stock traded within a daily range of ₹3,281.70 to ₹3,770.00, touching a fresh 52-week high of ₹3,374.00 during the session.
The broader market exhibited positive momentum as the Nifty advanced 1.23%, whereas the sector benchmark Nifty Pharma declined 0.52%. Gland Pharma's modest gain reflects relative resilience against the broader pharmaceutical sector's downward drift, building upon recent returns of 4.86% over the past 5 trading days and 7.60% over the past 20 trading days.
Recent fundamental context includes the company's financial performance for the quarter ended September 30, 2026, where revenue from operations rose 23% year-on-year to ₹18,336 million and profit after tax grew 58% year-on-year to ₹2,908 million. Additionally, the company announced the appointment of Mr. Xiao Le as Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 9, 2026, to oversee international M&A and investment opportunities.
1.25 lakh shares traded by 11 November 2026 · 10:30 AM IST. This compares with a 20-day average daily volume of 4.68 lakh shares (0.27 times). The five-day average daily volume was 8.48 lakh shares. Separately, the NSE report for 9 November 2026 showed 5.60 lakh shares delivered, representing 22.98% of that day’s traded volume. The same report recorded 216,218 trades.
The modest upward movement reflects continued positive sentiment from last week's strong Q2 financial results and the subsequent appointment of an international Chief Investment Officer, despite minor weakness in the broader pharma sector.
Latest Company Developments
Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 9, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across biopharma and healthcare services, holding degrees from Johns Hopkins University and MIT. He will lead M&A and strategic investments across the US, China, Singapore, and other international markets.
Strengthens leadership bandwidth for executing cross-border mergers, acquisitions, and strategic partnerships to support the company's global expansion.
The company reported its financial results for the quarter ended September 30, 2026, posting a 23% year-on-year increase in revenue from operations to ₹18,336 million. Profit after tax expanded 58% year-on-year to ₹2,908 million, supported by a 31% growth in the CDMO business and strong execution in core regulated markets like the US.
Demonstrates robust operational growth and margin expansion across key business segments, providing strong underlying fundamentals for the equity.
Gland Pharma submitted the scrutinizer's report regarding voting results from its postal ballot concluded on November 5, 2026. Members approved the ordinary resolution for the appointment of Mr. Xingli Wang as a Non-Executive and Non-Independent Director with the requisite majority.
Formalizes board composition changes aligned with promoter representation and corporate governance requirements.
Appointment of Mr Xiao Le as the Chief Investment Officer for Gland Pharma International Pte. Ltd (Wholly- owned subsidiary of Gland Pharma Limited), effective November 09, 2026
Five Stocks To Buy Today, November 11: Gland Pharma, Sansera Engineering, Union Bank, And More NDTV Profit
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 29.52% on 30 September 2026. This compares with 28.23% on 30 June 2026, a change of +1.29 percentage points.
The filing reported 31 MF/UTI holders.
Research & Brokerage Views
Gland Pharma stock jumps 12%, top midcap gainer after strong Q1; Jefferies upgrades to Buy, check target…
Historical Bulk / Block Deals
What to Watch Next
- Execution and scaling of international M&A initiatives under the newly appointed CIO
- Progress on U.S. FDA audit responses and establishment inspection reports for manufacturing facilities
- Commercialization timelines for co-development partnerships and new complex injectable launches
- Delivery volume trends and cash market participation relative to 20-day averages
Other Dated Coverage
More Gland Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Gland Pharma company news?
Gland Pharma announced the appointment of Mr. Xiao Le as the Chief Investment Officer for its wholly-owned subsidiary, Gland Pharma International Pte. Ltd., effective November 9, 2026. Mr. Xiao Le brings over 15 years of experience in investment and asset management across biopharma and healthcare services, holding degrees from Johns Hopkins University and MIT. He will lead M&A and strategic investments across the US, China, Singapore, and other international markets.
How strong was Gland Pharma’s trading volume?
1.25 lakh shares traded, 0.27 times the 20-day average daily volume. The price and volume data are dated 11 November 2026 · 10:30 AM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.